Hemostatic Agents and Prophylaxis

Recommendations
Supporting Materials
Panel
Update Log

Last Updated: November 18, 2024
First Published: November 18, 2024

Guidelines

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam eu turpis molestie, dictum est a, mattis tellus. Sed dignissim, metus nec fringilla accumsan, risus sem sollicitudin lacus, ut interdum tellus elit sed risus. Maecenas eget condimentum velit, sit amet feugiat lectus. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Praesent auctor purus luctus enim egestas, acscelerisque ante pulvinar. Donec ut rhoncus ex. Suspendisse ac rhoncus nisl, eu tempor urna. Curabitur vel bibendum lorem. Morbiconvallis convallis diam sit amet lacinia. Aliquam in elementum tellus.

WFH Guidelines in Practice

Frameworks

Guidelines

Hemostatic Agents Version 2020

Prophylaxis Version 2020

Key Messages

For Healthcare Professionals_HA Version 2020

For People with Hemophilia and Caregivers_HA Version 2020

For Healthcare Professionals_PXX Version 2020

For People with Hemophilia and Caregivers_PXX Version 2020

Media

Narrated Video Summary_HA

Narrated Video Summary Download_HA

Presentation Slide Deck_HA

Narrated Video Summary_PXX

Narrated Video Summary Download_PXX

Presentation Slide Deck_PXX

International

French

Healthcare Professionals_HAVersion 2020 Healthcare Professionals_PXXVersion 2020 People with Hemophilia_HAVersion 2020 People with Hemophilia_PXXVersion 2020 Guidelines Hemostatic Agents Version 2020 Guidelines Prophylaxis Version 2020 Video_HAVersion 2020 Video_PXXVersion 2020

Spanish

Simplified Chinese

Russian

Slides_HAVersion 2020 Slides_PXXVersion 2020 Video Download_PXXVersion 2020 Video Download_HAVersion 2020 Video_HAVersion 2020 Video_PXXVersion 2020

Arabic

Recommended Citation

(HA) Pipe, S.W., Carcao, M., Chew, K., Kaczmarek, R., Kitchen, S., Mahlangu, J., Ozelo, M.C., Suwantaroj, E., Windyga, J., Pierce, G. F., & Srivastava, A. (2020). WFH Guidelines for the Management of Hemophilia, 3rd Edition: Hemostatic Agents. Haemophilia, 26(Suppl. 6), 59–71. https://doi.org/10.1111/hae.14046

(PXX) Carcao, M., van den Berg, H.M., Gouider, E., Khair, K., Baarslag M.A., Bagley, L., de Paula Careta, F., Ljung R. C. R., Ragni, M.V., Santagostino, E., Pierce, G. F., & Srivastava, A. (2020). WFH Guidelines for the Management of Hemophilia, 3rd Edition: Hemostatic Agents. Haemophilia, 26(Suppl. 6), 72-84. https://doi.org/10.1111/hae.14046

Hemostatic Agents

Topic Panel Lead

Steven W. Pipe

Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan, USA

Topic Panelists

Manuel Carcao

MD, FRCPC

Department of Paediatrics
University of Toronto
Division of Haematology/Oncology
Hospital for Sick Children, Toronto, ON, Canada

Kim Chew

Lived Experience Expert

Kuala Lumpur, Malaysia

Radoslaw Kaczmarek

PhD

Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA

Steve Kitchen

PhD, FRCPath

Department of Coagulation, Sheffield Haemophilia and Thrombosis Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

Johnny Mahlangu

BSc, MBBCh, MMed, FCPath

Department of Molecular Medicine and Haematology, University of the Witwatersrand
National Health Laboratory Service, Johannesburg, South Africa

Margareth C. Ozelo

MD, PhD

INCT do Sangue Hemocentro UNICAMP, University of Campinas, Campinas, SP, Brazil

Ekawat Suwantaroj

Lived experience expert

Bangkok, Thailand

Jerzy Windyga

MD, PhD

Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland

Guidelines Co-Chair

Glenn F. Pierce

MD, PhD

World Federation of Hemophilia, Montreal, QC, Canada

Alok Srivastava

MD, FRACP, FRCPA, FRCP

Department of Haematology, Christian Medical College, Vellore, India

Prophylaxis In Hemophilia

Topic Panel Lead

Manuel Carcao

MD, FRCPC

Department of Paediatrics
University of Toronto
Division of Haematology/Oncology
Hospital for Sick Children, Toronto, ON, Canada

Topic Panelists

H. Marijke van den Berg

MD, PhD

PedNet Haemophilia Research Foundation, Baarn, the Netherlands

Emna Gouider

Medical School, University of Tunis El Manar, Hemophilia Centre, Aziza Othmana Hospital, Tunis, Tunisia

Kate Khair

PhD

Centre for Outcomes and Experience Research in Child Health, Illness and Disability Research Unit (ORCHID) and Great Ormond Street Hospital for Children, London, UK

Manuel A. Baarslag

Lived Experience Expert

Bemmel, the Netherlands

Lisa Bagley

Lived Experience Expert

London, UK

Francisco de Paula Careta

PhD

Department of Pharmacy and Nutrition, Federal University of Espirito Santo Alegre, Alegre, ES, Brazil

Rolf C. R. Ljung

MD, PhD

Department of Clinical Sciences – Pediatrics, Lund University, Lund, Sweden

Margaret V. Ragni

MD, MPH

Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

Elena Santagostino

Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

Co-Chair

Glenn F. Pierce

MD, PhD

World Federation of Hemophilia, Montreal, QC, Canada

Alok Srivastava

MD, FRACP, FRCPA, FRCP

Department of Haematology, Christian Medical College, Vellore, India

Prophylaxis and Hemostatic Agents Update, 2026

The WFH, in partnership with ISTH, EAHAD, EHC and NBDF, is in the process of updating the Prophylaxis and Hemostatic Agents Chapters. They have been combined into a single Chapter. The Public Comment Period is expected to open in August and will run for 3 weeks. Check back to find out more.

Topic Panelists

Full Name (Publication)	Credentials	Affiliation
Manuel Carcao (Topic Co-Lead)	MD, FRCPC, MSc	Division of Haematology/Oncology, Department of Paediatrics, and The Comprehensive Care Hemophilia Clinic, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Steven Pipe (Topic Co-Lead)	MD	Department of Pediatrics and Pathology and Hemophoilia and Coagulation Disorders Program, University of Michigan, Ann Arbor, MI
Rose Bender	MD, Msc, LEE	Yale University School of Medicine, Connecticut, USA
Pratima Chowdary (EAHAD Representative)	MD	Department of Haematology, Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, Cancer Institute, University College London, London.
Francisco de Paula Careta	PhD, lEE	Department of Pharmacy and Nutrition, Federal University of Espirito Santo, Alegre, Brazil
Amy Dunn (NBDF Representative)	MD	Division of Hematology/Oncology and Bone Marrow Transplant, Nationwide Children’s Hospital, Columbus, Ohio, USA Department of Pediatrics, The Ohio State College of Medicine, Columbus, Ohio, USA
Miguel Escobar	MD	Division of Hematology, Department of Pediatrics, McGovern Medical School at UTHealth, Houston, TX, USA Department of Pediatrics and Internal Medicine, Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA
Karin Fijn van Draat (ISTH Representative)	MD, PhD	Amsterdam UMC, University of Amsterdam, Emma Children’s Hospital, Pediatric Hematology, Meibergdreef 9, Amsterdam, Netherlands Sanquin Research, Department of Molecular Cellular Hemostasis, Amsterdam, the Netherlands
Emna Gouider	MD	Hematology biological department, Aziza Othmana Hospital, Tunis, Tunisia Universtiy of Tunis El Manar, Tunis, Tunisia
Radoslaw Kaczmarek	PhD, MSc, LEE	Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolois, Indiana, USA
Magdalena Lewandowska	MD	Innovative Hematology/Indiana Hemophilia Thrombosis Center, Indianapolis, Indiana, USA Indiana University, Indianapolis, Indiana, USA
Rolf C. R. Ljung	MD, PhD	Deparment of Pediatrics, Lund University, Lund, Sweden
Johnny Mahlangu	MBBCH, MMed, FCPath	Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa Clinical Haematology Unit, Charlotte Maxeke Johannesburg Academic Hospital, Parktown, South Africa
Maria Elisa Mancuso (EHC Representative)	MD, PhD	Center for Thrombosis and Hemorrhagic Diseases, IRCCs Humanitas Research Hospital, Rozzano, Milan, Italy Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
Margareth C. Ozelo	MD, PhD	International Hemophilia Training Centre (IHTC), Departments of Internal Medicine and Hematology, School of Medical Sciences, Hemocentro UNICAMP,University of Campinas, Campinas, São Paulo, Brazil
Margaret V. Ragni	MD, MPH	Department of Medicien and Translational Research and Division of Classical Hematology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Susie Shapiro (ISTH Representative)	MD, PhD	Oxford Haemophilia and Thrombosis Centre, Oxford University Hospitals, Oxford, UK
Alok Srivastava	MD, FRACP, FRCPA, FRCP	Department of Clinical Haematology, St. John’s Medical College Hospital,Bengaluru, Karnataka, India Haematology Research Unit, St. John’s Research Institute, Bengaluru, Karnataka, India
Ekawat Suwantaroj	LEE	National Hemophilia Foundation of Thailand, CITY, Thailand Thai Rare Disease Foundation, CITY, Thailand
Jerzy Windyga	MD, PhD	Department of Hemostasis Disorders and Internal Medicine; Laboratory of Hemostasis and Metabolic Disease, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
Glenn F. Pierce (Guidelines Chair)	MD, PhD, LEE	World Federation of Hemophilia, Montreal, QC, Canada

Hemostatic Agents and Prophylaxis

Guidelines

WFH Guidelines in Practice

Frameworks

Guidelines

Key Messages

Media

International

French

Spanish

Simplified Chinese

Russian

Arabic

Recommended Citation

Hemostatic Agents

Topic Panel Lead

Topic Panelists

Guidelines Co-Chair

Prophylaxis In Hemophilia

Topic Panel Lead

Topic Panelists

Co-Chair

Prophylaxis and Hemostatic Agents Update, 2026

Topic Panelists

WFH

Events

Useful Links